Format

Send to

Choose Destination
Br J Cancer. 2006 Apr 10;94(7):941-6.

Towards third generation matrix metalloproteinase inhibitors for cancer therapy.

Author information

1
CBCRA Program in Breast Cancer Metastasis, Department of Oral Biological & Medical Sciences, The UBC Centre for Blood Research, University of British Columbia, Vancouver, BC, Canada V6T 1Z3. chris.overall@ubc.ca

Abstract

The failure of matrix metalloproteinase (MMP) inhibitor drug clinical trials in cancer was partly due to the inadvertent inhibition of MMP antitargets that counterbalanced the benefits of MMP target inhibition. We explore how MMP inhibitor drugs might be developed to achieve potent selectivity for validated MMP targets yet therapeutically spare MMP antitargets that are critical in host protection.

PMID:
16538215
PMCID:
PMC2361222
DOI:
10.1038/sj.bjc.6603043
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Nature Publishing Group Icon for PubMed Central
Loading ...
Support Center